Despite fluctuations in policy, China's pharmaceutical industry revenue growth rate in 2012 will reach 23%, and it is expected that the increase in profits will be 18-19%. The low growth rate forecast has given pharmaceutical companies a certain amount of assurance.
The policy environment of pharmaceutical companies is gradually improving. He said that the "Health and Medical System Reform Plan and Implementation Plan" announced on March 21 this year had five major highlights, so this year the company is expected to step out of the "deepwater area."
Yu Mingde believes that the highlights of the policies worth paying attention to are: the government's investment in medical reforms has increased significantly. By 2015, this will be 50% higher than this year. The government will make up 360 yuan, and the market will expand by over 100 billion yuan; the “low price only bid†will disappear from the document. , Adhere to the priority of quality, reasonable price, and further improve the basic drug quality evaluation criteria and evaluation methods; to the international level of generic drugs, support in the pricing, bidding and procurement, and promote market mechanisms, and vigorously develop non-public medical institutions.
It is precisely from the interpretation of the above policy that Yu Mingde believes that this year's pharmaceutical industry environment gradually began to improve, and can achieve a forecast of 23% revenue growth and 18-19% increase in profit.
Even with double-digit growth, the challenges facing the Chinese pharmaceutical industry remain daunting.
Wang Xueqing, Division of Medicine of the Consumer Products Division of the Ministry of Industry and Information Technology believes that these daunting challenges are reflected in many aspects. First of all, the pharmaceutical technology innovation capability is very weak, R&D investment is low, R&D intensity only accounts for about 1% of sales revenue, and cannot be compared with the proportion of 15% of foreign patent pharmaceutical companies. The technological innovation system needs to be improved, product upgrading and technology upgrading, and key technologies in some industries will be difficult to break through for a long time.
Second, the long-term structure needs to be upgraded. Some major, multiple-disease drugs and high-end medical equipment rely on imports. The scale of biotech drugs is small, the development level of pharmaceutical preparations is low, the development and application of new technologies and new materials for pharmaceutical excipients and packaging materials are inadequate, and the added value of exported products is low.
Third, the degree of industrial concentration is low and companies are scattered. Fourth, the low level of repeated construction is serious. Fifth, the level of drug safety and security needs to be improved.
According to Xie Jili, an advisor to the China National Pharmaceutical Information Center, it is important to grasp the "inner context" of the policy. During the "Twelfth Five-Year Plan" period, the state has made clear the idea of ​​encouraging independent innovation and promoting industrial upgrading.
Wang Xueqing told reporters that in the future, the development priorities of the pharmaceutical industry policy include promoting the promotion of independent innovation capabilities, encouraging the development of biotech drugs and biomedical engineering industries, promoting the development of generic drugs, promoting mergers and reorganizations, and increasing industrial concentration.
Dust Collector ,Dust Collector Cyclone,Dust Collector System,Dust Collector Hose
AOBO New Material, Dust Collector Co., Ltd. , http://www.nbfilterm.com